612 related articles for article (PubMed ID: 7784095)
1. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
Pietras RJ; Arboleda J; Reese DM; Wongvipat N; Pegram MD; Ramos L; Gorman CM; Parker MG; Sliwkowski MX; Slamon DJ
Oncogene; 1995 Jun; 10(12):2435-46. PubMed ID: 7784095
[TBL] [Abstract][Full Text] [Related]
2. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
Kim HJ; Cui X; Hilsenbeck SG; Lee AV
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
[TBL] [Abstract][Full Text] [Related]
3. Alterations in transforming growth factor-alpha and -beta production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth.
Herman ME; Katzenellenbogen BS
Cancer Res; 1994 Nov; 54(22):5867-74. PubMed ID: 7954416
[TBL] [Abstract][Full Text] [Related]
4. Selective regulation of steroid receptor expression in MCF-7 breast cancer cells by a novel member of the heregulin family.
Mueller H; Kueng W; Schoumacher F; Herzer S; Eppenberger U
Biochem Biophys Res Commun; 1995 Dec; 217(3):1271-8. PubMed ID: 8554586
[TBL] [Abstract][Full Text] [Related]
5. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells.
van Agthoven T; van Agthoven TL; Portengen H; Foekens JA; Dorssers LC
Cancer Res; 1992 Sep; 52(18):5082-8. PubMed ID: 1516065
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
7. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells.
Kawai H; Li H; Chun P; Avraham S; Avraham HK
Oncogene; 2002 Oct; 21(50):7730-9. PubMed ID: 12400015
[TBL] [Abstract][Full Text] [Related]
8. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
9. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
10. FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells.
Johnson MR; Valentine C; Basilico C; Mansukhani A
Oncogene; 1998 May; 16(20):2647-56. PubMed ID: 9632141
[TBL] [Abstract][Full Text] [Related]
11. Genetic instability and the development of steroid hormone insensitivity in cultured T 47D human breast cancer cells.
Reddel RR; Alexander IE; Koga M; Shine J; Sutherland RL
Cancer Res; 1988 Aug; 48(15):4340-7. PubMed ID: 3390830
[TBL] [Abstract][Full Text] [Related]
12. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Tan M; Grijalva R; Yu D
Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
[TBL] [Abstract][Full Text] [Related]
13. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
15. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
16. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
Arpino G; Green SJ; Allred DC; Lew D; Martino S; Osborne CK; Elledge RM
Clin Cancer Res; 2004 Sep; 10(17):5670-6. PubMed ID: 15355892
[TBL] [Abstract][Full Text] [Related]
17. 9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein.
Rubin M; Fenig E; Rosenauer A; Menendez-Botet C; Achkar C; Bentel JM; Yahalom J; Mendelsohn J; Miller WH
Cancer Res; 1994 Dec; 54(24):6549-56. PubMed ID: 7987855
[TBL] [Abstract][Full Text] [Related]
18. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor alpha.
Kinoshita Y; Chen S
Cancer Res; 2003 Jul; 63(13):3546-55. PubMed ID: 12839940
[TBL] [Abstract][Full Text] [Related]
19. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]